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revision. Her access flow one month post revision was 980
ml/min.
DISCUSSION
Dr. Steve J. Schwab (Vice-Chairman, Department of
Medicine, Duke University Medical Center, and Professor
of Medicine, Duke University School of Medicine, Dur-
ham, North Carolina, USA): This case exemplifies the
current state of the art for the management of vascular
access for hemodialysis. The predominant form of vascu-
lar access currently in the United States is the polytetra-
fluoroethylene (PTFE) graft, constituting some 70% of
CASE PRESENTATION the total permanent access. Primary arteriovenous fistu-
las, although generally preferred, are used less oftenA 62-year-old black woman with end-stage renal disease
secondary to type-II diabetes mellitus began hemodialysis 2 because of late referral of patients to nephrologists, and
years ago. She presented to the Nephrology Service at Duke because an aging and diabetic population with a limited
University Medical Center with a serum creatinine of 8.6 mg/
number of suitable sites for the formation of primarydl; vascular access for hemodialysis was achieved via an internal
AV fistulas limits their formation. They currently consti-jugular, cuffed, Silastic catheter. A brachiocephalic, primary
arteriovenous (AV) fistula was attempted but failed to mature. tute less than 20% of the prevalent hemodialysis access
A left upper arm PTFE graft was subsequently placed. Hemodi- in the United States. This case also provides me an op-
alysis proceeded uneventfully, and she entered into a hemodial- portunity to discuss the current role of the tunneledysis vascular access monitoring protocol with dynamic venous
cuffed catheter in hemodialysis vascular access.pressure testing. On two later occasions, she underwent percu-
Complications of vascular access are not only a majortaneous transluminal angioplasty of a stenotic lesion 2 cm supe-
rior to the vein/graft anastomosis. In both instances, venous cause of morbidity in hemodialysis patients, but a major
dialysis pressure above the monitor threshold indicated the cost for the end-stage renal disease program. In its latest
presence of the lesion. Four months ago, venous dialysis pres-
report, the United States Renal Data System (USRDS)sure monitoring was changed to monitoring with ultrasound
estimated that the costs for access morbidity approachdilution access flow. Her access flow rates continued to decrease
on monthly readings, from 1020 ml/min to 750 ml/min over a $8000/patient/year at risk [1]. Remarkably, conservative
4-month period. Fistulography showed recurrence of the same estimates suggest that this figure represents 17% of the
stenotic lesion. Angioplasty was attempted, but the lumen was total spending for hemodialysis patients. Feldman [2,
not successfully reconstituted. She was offered elective surgical
3] and others [4–6] have reported that access-relatedrevision but declined. One month later, her access flow had
morbidity accounts for almost 25% of all hospital staysdecreased to 680 ml/min, and she presented with a thrombosed
arteriovenous graft. Pulse spray thrombolysis revealed a resid- for ESRD patients and may contribute to as much as
ual 95% outflow stenosis. The patient then elected surgical 50% of all hospitalization costs [2–7]. Using the prospec-
tively collected data from the Dialysis Outcome Practice
Patterns Study (DOPPS), Held has confirmed Feldman’s
Presentation of this Forum is made possible by grants from Merck and
observations [6]. Indeed, managed care organizationsCo., Incorporated; Astra Pharmaceuticals; Hoechst Marion Roussel,
Incorporated; Dialysis Clinic, Incorporated; and R & D Laboratories, planning for a capitated payment environment estimate
Incorporated. that as much as one-quarter of the total cost of end-
stage renal disease is spent on the maintenance of vascu-Key words: PTFE graft, AV fistula, AV graft, angioplasty, access
thrombosis, tunneled, cuffed catheter, end-stage renal disease. lar access in hemodialysis patients [7]. Thus, the mainte-
nance of access to the circulation is not only a major 1999 by the International Society of Nephrology
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Fig. 1. Intravascular ultrasound of fibromuscular hyperplasia in brachial vein at the vein graft anastomosis. Sphere in center of vein is the head
of the ultrasound catheter.
patient care concern, but also an enormous fiscal drain tomosis of the brachial artery with the basilic vein. The
disadvantage of this approach is that the vein runs on theon the end-stage renal disease program.
undersurface of the arm and is very difficult to cannulate.
Types of vascular access Native AV fistulas have the disadvantage of requiring a
long maturation time (3 to 6 months) and of not devel-The first described, and still the best, form of perma-
nent vascular access is the native arteriovenous fistula oping sufficiently in many older patients, especially dia-
betics. Thus, early referral, well before the need for dial-[8–10]. This access, constructed by the anastomosis of a
native artery with a native vein, can be created in either ysis, is required to successfully create native AV access
in most patients.a side-to-side or an end-to-side fashion. Three types of
native AV fistulas can be formed. The radiocephalic Synthetic internal AV fistulas, termed “AV grafts,”
can be placed in numerous positions in the arms andfistula is formed by the anastomosis of the radial artery
with the cephalic vein to form a large forearm vein suit- legs and across the anterior chest wall. The synthetic
portion of the graft is usually composed of PTFE [11,able for venipuncture [8]. An alternative type, which can
be successfully placed in many patients in whom venous 14–16], a compound synthesized by many manufacturers
and formed into both reinforced and nonreinforced con-and arterial structures are not suitable for a radiocephalic
approach, is a brachiocephalic AV fistula. This access is figurations. Advantages of using PTFE grafts are the
short maturation time (3 to 4 weeks) and the multipleformed by the anastomosis of the brachial artery with
the cephalic vein above the elbow. Thus, the vein runs potential access sites. Their overwhelming disadvantage
is their propensity for venous outflow stenosis causedover the anterior surface of the bicep and is suitable
for cannulation [11–13]. The third type of primary AV by endothelial and fibromuscular hyperplasia [7, 9, 10,
14–16].fistula, a brachiobasilic AV fistula, is formed by the anas-
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Fig. 2. Radiograph of outflow stenosis at vein
graft anastomosis in an AV graft before (A)
and after (B), opposite page, correction with
angioplasty. A. White arrowhead represents
location of occluding blood pressure cuff.
White arrow shows stenosis at vein graft anas-
tomosis. Black arrow represents AV graft.
Curved white arrow indicates proximal native
vein.
The third type of permanent vascular access, devel- similar results. At Duke, thrombosis accounted for 84%
of all AV access loss, at the Austin Clinic, 85%. Similarly,oped in the late 1980s, is the cuffed, tunneled, internal
jugular dialysis catheter [17–25]. Although capable of the DOQI-derived conclusion from several large investi-
gative efforts into the causes of thrombosis from Dukeproviding permanent vascular access, its overall perfor-
mance is inferior to the AV approach in all aspects [7, University, Austin Clinic, and University of California,
San Diego, indicate that more than 80% of access failures9, 10, 20–25]. Its principal role is as a “bridge” creating
immediate access to the circulation and allowing a were caused by outflow stenoses in the venous circula-
tion, 84%, 86%, and 92% at these institutions, respec-smooth clinical transition to the creation of a permanent
vascular access. tively [7, 14–16, 26–39]. These areas of stenosis generally
occurred at or near the vein/graft anastomosis, at areas
Access failure of vein bifurcation, at areas of calcified venous valves,
or at the site of a central venous cannulation [26–38].Failure of permanent vascular access in hemodialysis
Fewer than 2% of the total access failures resulted frompatients occurs for two reasons. Failure ensues in more
arterial stenosis. Fewer than 15% occurred without athan 80% of cases because a thrombotic episode cannot
clearly defined anatomic cause. Histologic evaluation re-be resolved [7, 9, 10, 14–16, 26–39]. Failure secondary to
vealed that endothelial and fibromuscular hyperplasiainfection or other complications occurs in approximately
15% to 20% of cases. Two large series of studies by was the leading cause of these venous outflow stenoses,
and that 50% to 70% of these stenoses occurred at ordifferent investigating groups (Duke University and
Austin Clinic), as collated by the Dialysis Outcome Qual- within 3 cm of the vein/graft anastomosis (Figs. 1 and
2) [14–16, 26–38]. Native AV fistulas lacking a vein/graftity Initiative (DOQI) for vascular access, found strikingly
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Fig. 2. B. White arrow shows stenosis post
angioplasty demonstrating restored venous
flow. (From Schwab SJ, Saeed M, Sussman
SK, McCann RL, Stickel DL: Transluminal
angioplasty of venous stenoses in polytetran-
fluoroethylene vascular access grafts. Kidney
Int 32:395–398, 1987.)
anastomosis had a lower rate of stenosis. Thus, access patency rate than do AV grafts (Fig. 3). Primary patency
reflects patency to the “initial intervention” on the ac-failure both in AV fistulas and AV grafts was secondary
to fibromuscular and intimal hyperplasia in the venous cess; initial intervention could be thrombolysis or elec-
tive angioplasty or surgery. Cumulative patency (definedcirculation. The potential causes of the endothelial and
fibromuscular hyperplasia will be discussed later in this as patency of the access regardless of the number of
interventions) revealed improved performance in AVForum.
How accurate is our information about the natural graft patency compared to AV fistulas (Fig. 4); however,
this improvement in AV graft patency was obtained byhistory of vascular access in hemodialysis patients? The
National Kidney Foundation developed evidence-based an increased number of access interventions. The proce-
dures required to maintain AV graft patency were three-practice guidelines on vascular access, the Dialysis Out-
come Quality Initiative, and formed the largest data base to sixfold higher than that needed to maintain patency
of primary AV fistulas. When center analysis was usedavailable on hemodialysis vascular access [7]. The guide-
line development team reviewed more than 3500 manu- (selecting data only from centers with an active prospec-
tive monitoring and preventive therapy plan) AV fistulasscripts in the course of its work. The working group that
constructed the guidelines comprised representatives and AV grafts had nearly equal cumulative patency rates
but at the expense of many more corrective proceduresfrom all professional disciplines involved in the forma-
tion, maintenance, and care of vascular access [7]. Sev- for AV grafts (Fig. 5). The 3-year cumulative patency
for AV grafts is generally 50%, even at the reportingeral key conclusions were reached. Native AV fistulas
(excluding fistulas that fail to mature in the first 60 days centers with the best outcomes [7]. Thus, even at superior
centers, only 50% of AV grafts generally survive longerfor successful initial cannulation) have a much longer
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than 3 years. Similar evaluation of studies examining stenosis. Access flow has been carefully validated by
using ultrasound dilution (abstract; Depner et al, ibid)cuffed, tunneled catheters found a much shorter lifespan
(on average, 12 months) and a much higher complication [41–45]. Conductance dilution and duplex colorflow
Doppler techniques also are available [43, 46, 47]. Col-rate than with AV access; thus, the DOQI discouraged
the use of these catheters for permanent access [7]. orflow Doppler has a confounding variable, however:
flow measurements are operator- and machine-depen-
Access salvage dent and have significant variability [48]. Data obtained
by ultrasound dilution suggest that access flow of lessProspective monitoring. Multiple investigators have
shown that thrombosis rates and AV graft patency im- than 600 ml/min in PTFE grafts is likely to lead rapidly
to access thrombosis. In addition, if the flow is less thanprove significantly when prospective screening tech-
niques are used to detect early outflow stenosis (abstract; 1000 ml/min, decrements in access flow of .15% are
equally likely to predict thrombosis and hemodynami-Depner et al, J Am Soc Nephrol 7:1405, 1996) [9, 10,
26–48]. European investigators have shown significant cally significant stenosis (abstract; Depner et al, ibid)
[41–45]. Monthly access flow monitoring seems to be anbenefit in prospective monitoring and ensuing early cor-
rection of incipient outflow stenoses of AV fistulas [36, adequate standard. Access flow should be measured at
standard times in the hemodialysis treatment to obtain39]. The theoretical benefits of graft and fistula monitor-
ing are that early fibromuscular hyperplasia can be suc- reproducible data and to avoid the variability induced
by decreases in cardiac output that are associated withcessfully treated by percutaneous techniques, thereby
preventing thrombosis and extending the life of the ac- ultrafiltration. In a study not yet published, we evaluated
ultrasound-dilution-determined access flow before andcess. Although not a cure, utilization of monitoring tech-
niques holds the promise of significantly increasing AV after angioplasty in a one-year prospective trial (Table
3). The mean percentage increase in flow following per-patency (Figs. 4 and 5).
The utility and validity of monitoring techniques for cutaneous transluminal angioplasty (PTA) was 33% in
AV fistulas and 41% in AV grafts. Failure to increasedetecting venous outflow stenoses in AV grafts and fistu-
las have gradually improved over the last decade (Table blood flow greater than 10% by PTA was associated with
a high likelihood of further fall in flow and thrombosis.1). The earliest technique used sequential measurements
of dynamic venous dialysis pressure [26]. The approach Corrective angioplasty, although beneficial, failed to re-
store flow to peak levels. Regardless of the mode ofhad the advantage of being inexpensive and readily avail-
able, but it required slowing blood flows to obtain repeti- monitoring, with a single exception [49], investigators
have found significant improvements (40%–80%) in cu-tive measurements, and use of the venous drip-pressure
monitor of the hemodialysis machine resulted in mea- mulative access patency when prospective monitoring
techniques are combined with early correction of outflowsurements that were quite variable. Thus, the confound-
ing variables introduced by differences in blood flow, stenosis using either angioplasty or surgical revision
[26–40].length and type of tubing, and type of monitor all needed
to be taken into account in using this technique [26, Treatment of outflow stenoses. As I have said, hemo-
dynamically significant venous outflow stenoses must be28]. This technique identified stenoses after a significant
stenosis already had occurred, and was most accurate treated to avoid access thrombosis. If not successfully
treated, when a critical reduction in venous diameterfor vein/graft stenoses, but it missed stenoses farther up
the extremity, where collateral circulation could allow occurs, thrombosis ensues and flow ceases. Hemody-
namic significance has been defined by access flow as welldissipation of the venous pressure. Nonetheless, most
studies indicated that, despite its shortcomings, the tech- as by venous dialysis pressure, as I have just discussed
[26–40]. To date, no data have convincingly demon-nique significantly improved access patency (Table 2) [7,
26, 28]. strated that correcting mild stenoses, that is, venous nar-
rowings without hemodynamic significance, is of anyThese techniques were supplanted by specialized de-
vices for measuring static venous pressure or venous value. Stenoses of 50% to 70% of lumen diameter re-
spond reasonably well to transluminal angioplasty [7,pressure at blood flows of 0 ml/min [27]. Because these
devices avoided the variables induced by blood flow and 26–37, 39]. Mean duration of patency following the first
angioplasty of a stenosis of 50% to 70% of lumen diame-the dependency on needle size, and because they used
a single standard-pressure transducer, they increased the ter is approximately 6 months [7]. Thus, repetitive angi-
oplasties frequently are necessary. Because interventionaccuracy of access monitoring [27]. Measuring static ve-
nous dialysis pressure was dramatically simplified re- that does not improve hemodynamic parameters is of
little value, successful intervention requires return ofcently; it can now be performed without separate devices
[40]. the hemodynamic monitoring parameter, such as access
blood flow, to normal. Despite one favorable study [39],Direct intra-access measures of blood flow are cur-
rently the most accurate method for detecting access the DOQI consensus is that the use of metallic stents
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Fig. 5. Cumulative patency of AV fistulas and AV grafts with prospec-Fig. 3. Primary unassisted patency of AV fistulas and AV grafts. Solid
tive monitoring and intervention. Solid line represents AV fistula pa-line represents AV fistula patency. Dashed line represents AV graft
tency. Dashed line represents AV graft patency. AV fistula patencypatency. AV fistula patency excludes fistulas that did not mature suffi-
excludes AV fistulas that did not mature sufficiently to allow initialciently to allow initial cannulation. Graph derived from summed data
cannulation. Cumulative patency reflects patency from initial cannula-analysis from the Vascular Access DOQI [7]. Primary patency reflects
tion to abandonment or removal of access. AV graft intervention (proce-patency from initial cannulation to first intervention. First intervention
dure) rate . 6 3 AV fistula intervention rate.could reflect thrombosis, removal, angioplasty, or surgical revision.
Table 1. Prospective monitoring of AV access:
The progress of technology
Dynamic venous pressure [26]a
Static venous pressure [27]
Intra-access blood flow [43, 44]
a Numbers in brackets refer to references
lent option. Theoretically, the placement of a stent in
an abnormal vascular bed could serve as a powerful
mitogen for further hyperplasia and dysplasia. This does
appear to be the case in most studies, which show dimin-
ished rather than increased patency when stents are em-
ployed in nonelastic lesions [50, 51]. Stents, however, do
improve patency rates in elastic stenoses. By definition,
elastic stenosis returns after angioplasty to the originial
lumen diameter. Thus elastic stenoses do not respond
to angioplasty alone. Elastic stenoses make up 20% toFig. 4. Cumulative patency of AV fistulas and AV grafts. Solid line
represents AV fistula patency. Dashed line represents AV graft patency. 25% of all venous stenoses (Fig. 6). The ideal locations
AV fistula patency excludes AV fistulas that did not mature sufficiently for such stent use are central veins, where surgical revi-to allow initial cannulation. Graph derived from summed data analysis
sion options are limited. Recurrent stenosis of centralfrom the Vascular Access DOQI [7]. Cumulative patency reflects pat-
ency from initial cannulation to abandonment or removal of access. vein elastic lesions occurs even after stenting, so ongoing
AV graft intervention (procedure) rate . 3 3 AV fistula intervention
monitoring is required.rate.
Not surprisingly, severe outflow stenoses (.90% of
the lumen diameter) generally are more likely to throm-
bose, and they also are more resistant to percutaneous
angioplasty than are less severe stenoses detected pro-generally has been of little value in improving access
spectively (abstract; Middleton et al, J Am Soc Nephrolpatency after angioplasty. Stents prevent surgical
79:A0838, 1414, 1996) [49, 52]. Typically, only a 40%revision of the involved area; thus their value is minimal
in peripheral stenoses, where surgical revision is an excel- 3-month patency is achieved when angioplasty is em-
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Table 2. Thrombosis and fistula replacementa
Patient years Episodes of Thromboses Fistulas Replacement
of dialysis thrombosis per patient/year replaced per patient/year
1985–1986b
12 months 85.3 52 0.61 22 0.26
1987–1988c
32 months 265.0 52 0.20 19 0.07
a From Ref. 26. This prospective study used dynamic venous dialysis pressure and preventive angioplasty and surgical access revision
b Pre-study retrospective control data
c Study data
Table 3. Access flow before and after angioplastya pulse-spray thrombolysis or a specific clot-macerating
device [32, 33, 53, 54]. In experienced centers, 85% toAV fistula AV graft
Peak flow postplacement Peak flow postplacement 90% of AV graft thrombosis episodes are resolvable
940 ml/min (N 5 3) 1320 ml/min (N 5 14) with any of these techniques [7, 11, 32, 33, 53, 54]. The
Pre-angioplasty Pre-angioplasty more important issue is treatment of the underlying ste-
670 ml/min (N 5 3) 760 ml/min (N 5 14)
nosis following resolution of the thrombus. Failure toPost-angioplasty Post-angioplasty
890 ml/min (N 5 3) 1070 ml/min (N 5 14) correct the underlying stenosis results in rapid re-throm-
bosis within days to weeks [7].a Mean access flow was determined by ultrasound dilution
In short, salvage techniques and strategies currently
allow us to extend the life of 70% of AV grafts for as
long as 3 years (Fig. 5) [7, 36–39]. These salvage proce-
dures also can be used with AV fistulas, although with
less success. The long-term key to access viability, how-
ever, is not treating progressive venous stenosis (al-
though that is required today) but preventing the endo-
thelial and fibromuscular hyperplasia that leads to the
vast majority of access failures. I will now turn to a
discussion of the cellular and subcellular events that lead
to venous stenosis, and the possibility of preventing fibro-
muscular hyperplasia.
The prevailing consensus is that venous stenosis is
caused by endothelial injury and vascular smooth muscle
hyperplasia in areas where flow turbulence, vessel
stretch, and shear stress occur. Many instances of outflow
Fig. 6. Central vein stenosis recurrence rate following angioplasty or stenosis occur at such locations, but little stenosis devel-
angioplasty and use of a wall stent. (From Ref. 52.) ops at the equally turbulent artery/graft anastomosis or
at the site of the artery/vein anastomosis in the AV
fistula [7, 14–16, 26–39]. Thus, additional factors must
be present for hyperplasia to occur. Each venipunctureployed for these lesions [7]. The surgical data are less
of the hemodialysis access forms a localized platelet plug,clear, but preliminary observations suggest that surgical
with resultant exposure of the downstream vessel to arevision holds much greater promise, with 6- to 12-month
host of platelet-derived cytokines such as platelet-patency rates of 60% to 70% reported in patients with
derived growth factor (PDGF). Windus has shown thatthese severe stenoses (abstract; Middleton et al, ibid)
platelets do not deposit directly at the vein/graft anasto-[49, 52].
mosis [55]. In a series of elegant studies, HimmelfarbAccess thrombosis in AV grafts can be successfully
and Couper have elucidated the potential cause of thistreated with either surgical embolectomy or with phar-
phenomenon [56]. Previously, Sreedhara and associatesmacologic or mechanical thrombolysis. Thrombectomy
had reported that high-dose dipyridamole decreased ac-entails incising the graft and inserting an embolectomy
cess thrombosis at new, but not at previously established,balloon to clear the clot from the thrombosed access.
AV grafts [57]; the reasons for this observation are un-“Pulse spray” thrombolysis uses pulsed injections of uro-
clear. The observations by Himmelfarb and Couper sug-kinase via crossed catheters in the clotted access graft
gest that the mechanism for this effect might not beuntil the clot is dissolved (Fig. 7). Mechanical thromboly-
sis uses either pulsed saline in a technique similar to related to the effect of dipyridamole on coagulation, but
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Fig. 7. Schematic drawing of pulse spray
thrombolysis of an AV graft. (Reprinted with
permission from AngioDynamics, Inc., Glens
Falls, New York.)
Table 4. Maintaining access patency to minimize turbulence and reduce vessel wall injury.
A recently developed “venous flare” AV graft holdsProspective monitoring for stenoses (see Table 1)
Therapy of stenoses promise and is currently in clinical trials [59]. That we
Percutaneous angioplasty could prevent this injury, rather than merely react to it,Use of stents for elastic stenoses
appears a very real possibility for the future.Surgical revision
Prevention
Radiation
SummaryGrafts designed to minimize turbulence
Gene therapy Access to large blood vessels capable of providing
Pharmacologic therapy
rapid extracorporeal blood flow is essential for mainte-Cytokine inhibitors
nance hemodialysis. Access to the circulation is still best
provided by native AV fistulas, but AV grafts offer an
acceptable alternative. Efforts at encouraging earlier re-
ferrals to nephrologists likely will facilitate preservationrather to an inhibitory effect of dipyridamole on platelet-
of vascular access sites and will allow AV fistulas to bederived cytokines, which stimulate endothelial and
placed in a higher percentage of cases; the latter goalfibromuscular hyperplasia in the vessel wall in response
was one of the primary recommendations of the DOQIto turbulence injury. The theory that vascular smooth
[7]. Recent data from the DOPPS study confirm thesemuscle hyperplasia reflects a response to injury in which
predictions [6]. Patients referred early to a nephrologistPDGF is prominent suggests that vein stenosis is prevent-
are 4 times more likely to have a permanent access placedable. Regardless of the mechanism, these theories open
prior to starting dialysis and are 9 times more likely tothe possibility that fibromuscular hyperplasia could be
have an AV fistula [6]. Increasing the percentage ofinhibited by pharmacologic therapy that will inhibit the
native AV fistulas among dialysis patients in the US isdevelopment and progression of outflow stenosis.
an enormous step forward in decreasing patient morbid-Another approach to the elimination of fibromuscular
ity and cost to the ESRD system. A goal of 40% AVhyperplasia is the use of radiation at areas of turbulence
fistulas in the US hemodialysis population is attainableto minimize vein/graft stenosis (Table 4). Prospective
over the next 3 years if patients are referred to nephrolo-clinical studies using these novel therapies represent a
gists early. I would argue (as did DOQI) that such refer-major step forward in our thinking and hold great prom-
ral should occur when the serum creatinine concentra-ise for our patients and for the ESRD system. Equally
tion reaches 3–4 mg/dl. In addition, strategies forexciting is the promise of gene therapy, as proposed by
prospective detection of hemodynamically significantSukatme in a recent Nephrology Forum [58]. Yet another
possibility is that the AV access itself can be modified outflow stenoses, when combined with pro-active correc-
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tion of this offending lesion, significantly improve access know that venous segments shown radiographically to
be 50% blocked are often, but not always, associatedpatency and should be universally adopted.
The morbidity and costs associated with maintenance with decreased access flow. We also know that when
these 50% venous stenoses are corrected, access flowof vascular access constitute an enormous burden both
for our patients and for the end-stage renal disease sys- improves significantly and access patency improves.
Dr. Andrew J. King (Division of Nephrology, Newtem. Significant advances have occurred in our under-
standing of AV access failure, and our therapeutic tech- England Medical Center): If you go to any dialysis unit
in the United States, you likely will find a subgroup ofniques have improved significantly. The ideal approach,
however, is prevention of the endothelial and fibromus- patients who are receiving long-term systemic anticoagu-
lation therapy with warfarin (Coumadin). Do you thinkcular hyperplasia that leads to the vast majority of access
failures. Vigorous basic science investigation of vascular there is an appropriate role for these agents in patients
with access dysfunction? Do data support the long-termbiology and active clinical investigation of medical and
surgical therapy are required to eliminate this bane of use of Coumadin?
Dr. Schwab: The data on systemic anticoagulation forour patients’ existence.
improving access patency are very limited. The DOQI
panel wanted to make statements dealing with anticoagu-
QUESTIONS AND ANSWERS
lation, but the published literature was inconclusive.
Dr. John T. Harrington (Dean, Tufts University Thus the DOQI panel lacked evidence to guide them
School of Medicine, Boston, Massachusetts): The access in making an evidence-based statement. In addition, a
devices that we use have been around a long time. The consensus could not be reached. It is our practice to
1960 external Scribner shunt has come and gone; the anticoagulate only patients who develop repetitive
AV fistula dates from 1966; and the Gore-Tex graft has thrombosis without an anatomic stenosis.
been with us for more than 20 years. Why don’t we have Dr. Ajay Singh (Division of Nephrology, New En-
anything new in the access realm? Is anything likely to gland Medical Center): I have two questions. There seems
come down the pike in the next 5 years that will prevent to be a tremendous variability among centers in the
us from having to deal with all of the issues that you United States, and also between centers in the US and
talked about? abroad, on fistula creation rates. One reason you men-
Dr. Schwab: I think it is unlikely. The latest device tioned is early referral. Could you elaborate on some of
that has come on the market that is widely used is the the other reasons why such variability exists?
Silastic/silicone cuffed-tunneled cathether. These cathe- Dr. Schwab: We believe that there are multiple rea-
ters serve best as an access bridge to permanent access. sons why the United States lags in AV fistula formation.
Comparative trials of new AV graft materials have been One reason is that we tend to have a much higher inci-
ongoing. To date none has emerged as superior to PTFE. dence of diabetes as a cause of ESRD and a much higher
The only new improvement that appears promising is acceptance rate for dialysis than do most other countries.
modifying the vein graft anastomosis, by so-called flares Fistulas develop less well in an aging diabetic population.
or inserts, which may minimize turbulence. In addition, A second reason is that in the US, patients are referred
several companies are starting clinical trials with a totally to nephrologists late in the course of their disease. This
subcutaneous hemodialysis catheter port. Nonetheless, late referral has prompted the use of rapidly maturing
the Cimino fistula is still by far the most trouble-free rather than slowly maturing accesses. A third reason is
long-term access device available. that brachial AV fistulas, which can be formed in older
Dr. Harrington: You commented on the difference diabetics whereas Cimino fistulas cannot, are not widely
between 50% and 80% stenosis. Fifty percent stenosis used in the United States.
of the access marks the time when you would like inter- The DOQI panel thought the quickest way to increase
vention to begin; 75% to 80% stenosis is where disasters the percentage of patients receiving AV fistulas would
are likely to take place fairly soon. Do we know enough be to institute a change in referral patterns. I believe
about the rate of progression from 50% to 80% stenosis that nephrologists should, at the very latest, see patients
so that if you find someone with 50% stenosis, you can by the time they develop a serum creatinine of 4 mg/dl.
state that within 3, 6, or 9 months that stenosis will A goal of 40% AV fistulas in the prevalent hemodialysis
become 80%, or is the time course unpredictable? population (compared with 17% currently) is a reason-
Dr. Schwab: It should be predictable. Unfortunately, able goal for 3 years from now if early referral can be
we currently do not have the information at hand to accomplished.
make a rational prediction about either the rate of pro- Dr. Singh: Can you update us on anti-endothelial anti-
gression of stenosis or what level of stenosis is associated bodies or protein S deficiency and their association with
with a thrombosis. We do know that AV grafts clot graft thrombosis?
Dr. Schwab: A series of hypercoagulable states (anti-readily at blood flows of less than 600 ml/min. We also
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phospholopid antibody, etc.) lead to an increase in veno-venous. Similarly, in patients with arterial-arterial
bypass, again it is the outflow end that always has thethrombosis in the absence of outflow stenosis in a small
subset of patients. I say a “small” subset of patients problem, even in the absence of the needle sticks that
bedevil AV fistulas. I always have been amused overbecause when the DOQI panel tried to determine from
the published literature how often thrombosis occurs some of the statistics, while not doubting for a second
that AV fistulas are superior to grafts. Patients who tendwithout significant stenoses, they concluded that this
event occurred in fewer than 10% of patients with throm- to have the better veins are also younger, more robust
patients and thus likely to be transplant patients. Onbosis. The working group felt that the principal problem
wasn’t hypercoagulability but rather failure to deal with the basis of Kaplan-Meiers’ statistics, younger transplant
patients are recorded at the time they get their transplantthe outflow stenosis that caused the thrombosis.
Dr. Andrew S. Levey (Division of Nephrology, New as having patent fistulas. By definition, the fistulas never
fail because of the transplant. There are additional biasesEngland Medical Center): You have come to a very logi-
cal set of conclusions. I would like to focus on your when access policies differ. If you have an older patient
with poor veins, and you have an active peritoneal dial-recommendations for prospective monitoring and early
interventions on PTFE grafts. We all agree that random- ysis program, sometimes you don’t try as hard to keep
a graft or a fistula patent.ized trials yield the best kind of evidence. You’re making
recommendations on the basis of non-randomized trials. In addition to age and diabetes, what are your thoughts
about the import of obesity as American beefs up andClearly, some of the results are striking but, as you point
out, there is a sevenfold increase in the number of proce- body mass index soars? I would have thought that at
some point, body mass index, perhaps over 30, woulddures required to maintain graft access patency. Have
you done a cost-effectiveness analysis to compare the become a factor. Finally, is it ever too early to create
an AV fistula? Why not put it in whenever the serumstrategy of monitoring and early intervention versus ac-
cess de-clotting and revision only after graft thrombosis? creatinine is elevated?
Dr. Schwab: The relationship between patient sizeDr. Schwab: Anatole Besarab and colleagues con-
ducted a well-constructed cost analysis of the use of static and access outcome has not, to my knowledge, been
studied. Everyone thinks that there’s an inverse relation-venous dialysis pressure monitoring [27]. They found
that cumulative costs were substantially less with pro- ship, in that as patients become larger, access outcomes
are worse. Unfortunately, there’s little in the literaturespective intervention than with a conservative approach
because aggressive intervention minimized unscheduled to prove the point. Question two is, “when do you place
an AV fistula?” The DOQI workgroup concluded that,thrombotic events and minimized hospital days. That is
the only study that has specifically addressed cost. The unlike an AV graft, there was little evidence that placing
an AV fistula early caused premature access failure.question you are asking is, are we merely substituting
one procedure for another? We might be. I would also There was also very little evidence that placing an AV
fistula early led to significant cardiovascular abnormali-argue that even if that were the case, we are substituting
an elective procedure for an urgent and unscheduled ties. The working group concluded that by placing a
primary AV fistula in a patient with a serum creatinineprocedure.
Dr. Richard Roher (Chief, Division of Surgical of 4 mg/dl, one optimizes the chance of maintaining a
functioning AV fistula when the need for dialysis arises.Transplants, New England Medical Center): I congratu-
late you on a thorough review of the AV access field. Preliminary observations from the DOPPS study suggest
that early referral to a nephrologist dramatically in-From my perspective I have no major argument with
your conclusions. I might add as well that dialysis patients creases the likelihood of an AV fistula being present
when dialysis is started [6].all should have their access planning integrated with
their transplant plans, because many could even avoid Dr. Harrington: DOQI recommends referral to a
nephrologist when the serum creatinine is 4 mg/dl. Thedialysis access. Also, my view is that we should view
catheters in the great veins as completely unnecessary recommendations don’t explicitly suggest placing a fis-
tula around the time the patient first sees a nephrologist.even though we know that in the real world they are
needed from time to time. But we should view every Am I wrong about that?
Dr. Schwab: No. You are correct. The reason behindone of them as indicative of our failure to make timely
provisions for appropriate dialysis access. that is as follows: If a patient has a creatinine of 4 mg/dl
and has potential living-related donors, we think it isI have a couple of observations and a couple of ques-
tions. The causes of intimal and fibromuscular hyperpla- unnecessary to form an AV fistula.
Dr. Saad Al Shohaib (Consultant Nephrologist, Na-sia that lead to loss of various conduits in other areas of
surgery are fascinating. We see it all the time in our liver tional Guard King Khalid Hospital, Jeddah, Saudi Ara-
bia): I have a comment and a question. In Saudi Arabiapatients, whom we transplant with their TIPS, which
always stenose at the outflow end even though they’re the situation is somewhat different. Patients are referred
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quite late to the nephrologist. It is not unusual to see a tion into the graft prior to placement. With radiation
therapy, there are two options. One is the techniquepatient for the first time whose serum creatinine level
exceeds 10 mg/dl. In a situation like this, central lines used in the coronary circulation, in which external beam
therapy is not an option; radioactive capsules are floatedare often left longer than usual, thus causing more com-
plications, including infections, venous stenosis, and to the area of angioplasty for controlled periods after
the angioplasty. That certainly is possible for vein graftthrombosis.
My question is this: do diabetics tend to have a higher anastomoses, but the second option, external beam radi-
ation, is easier and is possible in hemodialysis AV access.rate of access problems and complications, particularly
re-stenosis? Dr. Singh: I recall that that there seems to be some
association between the dose of erythropoietin givenDr. Schwab: A study by Windus and associates sug-
gests that type-I and type-II diabetics have more access intravenously and the potential for stenosis. Are there
some data to support that? If there are, and given themorbidity than do nondiabetics [60]. The other factor
associated with adverse outcomes was age. fact that there is evidence suggesting that you get higher
hematocrits if you use lower doses of Epo subcutane-Dr. Klemens Meyer (Division of Nephrology, New
England Medical Center): We know that people whose ously, shouldn’t we all use subcutaneous Epo in outpa-
tients?veins have been damaged by venipuncture can have trou-
ble forming an AV fistula, but what about the patients Dr. Schwab: Let me deal with your question in two
parts. First, what is the potential of erythropoietin as awho have not had repeated venipunctures? What does
it mean to have “bad veins?” Why do elderly diabetics mitogen for fibromuscular hyperplasia? The evidence
is indirect. No prospective clinical trials have shown anot form usable fistulas?
Dr. Schwab: I think the answer is that we don’t know. difference in thrombosis rates as a function of Epo dose
or of how Epo is administered. No convincing studiesWe do know that as you age, arterial flow diminishes
and arteries become less distensible. Whether diabetics have suggested that increasing the hematocrit as high as
36% has any significant effect on the thrombosis rate.don’t form AV access as well as nondiabetics because
of either arterial or venous problems or both is unclear The Normal Hematocrit Cardiac Trial showed that pa-
tients randomized to a hematocrit of 42% 6 3% had ato me. Perhaps Dr. Rohrer has an opinion.
Dr. Rohrer: I think there is a metabolic defect in statistically greater likelihood of access thrombosis than
did those randomized to the lower hematocrit target [61].these patients, and also in lupus patients, that affects
their vessels. But I cannot define it well. There is some- The reason for the greater thrombosis rate, be it more
intravenous iron, much higher Epo doses, or a higherthing about their vessels, too fragile or too small in a
predictable sort of way time after time, that makes them hematocrit, is unknown. Second, the DOQI panel for
anemia suggested that we should convert to subcutane-simply fail to mature.
Dr. Meyer: What’s your approach to the patient ous Epo dosing, primarily because we will save substan-
tial sums of money while arriving at the same hematocritwhose fistula doesn’t develop? Do you work that patient
up? Do you do an ultrasound? Do you do a venogram? target.
Dr. King: You alluded to the data from JonathanOr do you just wait a few weeks to months and then go
higher in the arm or go to a graft? Himmelfarb on endothelial hyperplasia [56], but of
course the pathologic lesion is primarily vascular smoothDr. Schwab: The literature suggests that primary AV
fistulas can be salvaged by identifying and tying off collat- muscle hyperplasia. In your discussion, you suggested
that the hyperplasia is mediated by growth factors, in-eral vessels so that the blood flow is forced to flow along
a single vein. Our practice is, if a radiocephalic fistula cluding PDGF. Could you elaborate on that hypothesis
and the purported cytokines involved?does not develop in 3 months, we either revise it as I
outlined earlier or form a brachiocephalic fistula on the Dr. Schwab: Himmelfarb demonstrated recently in
Kidney International that PDGF stimulated smooth mus-same side.
Dr. Ronald D. Perrone (Division of Nephrology, cle proliferation in cell culture [56]. He then showed that
you could inhibit this hyperplasia almost completely byNew England Medical Center): Could you comment on
how you deliver bioactive agents into a graft? What sort the use of pharmacologic doses of dipyridamole.
Dr. Al Shohaib: When you say that patients shouldof technology has been developed to do this? Are they
systemically administered, or are they administered lo- have access established when the creatinine is around 4
mg/dl, shouldn’t one take into consideration the rate ofcally, continuously infused, impregnated, or how?
Dr. Schwab: The agents that are coming to trial now progression of the renal disease? One patient with a
serum creatinine of 4 mg/dl might require dialysis withinall are substances that are taken orally, once or twice
per day. Gene constructs, assuming that they come into a few months, whereas another might remain stable for
a few years.use, presumably will be delivered directly to vein anasto-
moses by ultrasound-directed puncture or by impregna- My second question is about patients with polycystic
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considering access placement, understanding that AV Am Soc Nephrol 3:1–11, 1992
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Am J Kidney Dis 21:457–471, 1993knowledge, there is no evidence that polycystic kidney 11. Harland RC: Placement of permanent vascular access devices:
disease per se is associated with reduced vascular access Surgical consideration. Adv Renal Replace Ther 1:99–106, 1994
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rience with the brachiocephalic fistula. Ann R Coll Surg EnglDr. Meyer: Is there any evidence that chronic trauma,
68:203–206, 1986
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cates that excessive pressure, mediated either by digital Kittur D: Polytetrafluoroethylene graft survival in hemodialysis.
JAMA 249:219–222, 1983pressure or by a hemostasis clamp, will lead to thrombo-
15. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarussis in the absence of stenosis. Indeed, studies from our
JM, Tilney NL: Vascular access for hemodialysis: Patency rates
center over the last 5 or 6 years have shown repeatedly and results of revision. Ann Surg 202:235–239, 1985
that the percentage of nonanatomic or nonstenosis 16. Etheredge EE, Haid SD, Maeser MN, Sicard GA, Anderson
CG: Salvage operations for malfunctioning polytetrafluoroethy-thrombosis is higher when a new unit opens, and dimin-
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